Welcome to our dedicated page for Quanterix SEC filings (Ticker: QTRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Quanterix Corporation filings document the regulatory record of a life sciences company built around ultra-sensitive biomarker instruments, consumables, assay services, and clinical laboratory testing. Its Form 8-K disclosures include operating and financial results, material-event reports, clinical or regulatory disclosures, capital-structure items, and leadership or board changes.
Proxy materials for QTRX describe annual meeting matters such as director elections, advisory executive compensation votes, auditor ratification, equity incentive plan approvals, and governance provisions. The filing record also covers shareholder voting results and charter-related governance matters, providing formal disclosure of the company’s board structure, compensation framework, ownership voting mechanics, and public-company controls.
Quanterix Corporation appointed Anthony Catalano as its new Chief Operating Officer effective May 14, 2026. He brings prior leadership experience from Flagship Pioneering, Akoya Biosciences, Bruker Cellular Analysis and Revvity.
Under his employment agreement, Catalano will receive a $400,000 annual base salary, a $50,000 cash sign-on bonus and eligibility for an annual performance bonus targeted at up to 50% of base salary. He also received restricted stock units equal to 0.30% of Quanterix common shares outstanding on his start date, vesting in four equal annual installments.
If the company terminates him without Cause or he resigns for Good Reason, he is entitled to six months of base salary continuation, a pro-rated target bonus for the year of termination and subsidized health benefits. If such a termination occurs in connection with a Change-in-Control, salary continuation extends to nine months and all outstanding time-based equity awards become fully vested. Michael Miller, the former Chief Operating Officer, has moved to the role of Chief Technology and Products Officer.
Quanterix Corp Chief Financial Officer Vandana Sriram reported routine equity compensation activity involving restricted stock units (RSUs). On May 15, 2026, RSUs converted into common stock in several tranches, including 1,056, 514, and 263 shares, reflecting scheduled vesting.
To cover tax obligations, the filing shows share dispositions of 315, 154, and 79 shares of common stock at $2.75 per share, characterized as tax-withholding transactions rather than open-market sales. Following these transactions, the CFO directly held 28,897 shares of Quanterix common stock, while additional RSUs remain outstanding and continue to vest over time.
Quanterix Corp Chief Technology Officer Michael Francis Miller reported routine equity compensation activity. On May 15, 2026, restricted stock units vested and were converted into 1,558 shares of Common Stock, while 467 shares were withheld at $2.75 per share to cover tax obligations. After these transactions, he directly owned 32,694 Common shares and 760 restricted stock units that may vest later.
Quanterix Corp Schedule 13G/A amendment shows Portolan Capital Management, LLC and George McCabe beneficially own 2,945,823 shares of Quanterix Common Stock, representing 6.25% of the class. The filing lists sole voting and dispositive power of 2,945,823 shares for each Reporting Person. The cover identifies CUSIP 74766Q101 and the principal business address for the Reporting Persons as 2 International Place, FL 26, Boston, MA 02110. The statement is signed by George McCabe on 05/15/2026.
Ameriprise Financial, Inc. filed Amendment No. 5 to a Schedule 13G/A reporting shared voting and dispositive power over 3,542,374 shares of Quanterix Corp common stock (CUSIP 74766Q101), representing 7.5% of the class. The filing states that AFI disclaims beneficial ownership of the shares reported and incorporates the cover‑page rows by reference.
Quanterix Corporation announced that Chief Financial Officer and Treasurer Vandana Sriram will leave the company, with her role ending on June 15, 2026. She will stay through that date to support a smooth transition while the company conducts a search for her successor with an executive search firm.
Under her employment agreement, Ms. Sriram will receive 12 months of base salary, an amount equal to her annual target bonus for 2026, and subsidized health benefits for 12 months. The company states that her departure is not related to any disagreements regarding accounting practices, financial statements, internal controls, or operations, and highlights that Quanterix remains on solid financial footing with a focus on cash flow breakeven and synergy targets.
Ameriprise Financial, Inc. filed an Amendment No. 6 to a Schedule 13G/A reporting shared voting and dispositive power over 990,224 shares of Quanterix Corp common stock, representing 2.1% of the class. The filing lists Quanterix's principal executive office at 900 Middlesex Turnpike, Billerica, MA and states that AFI disclaims beneficial ownership of the reported shares.
Quanterix Corporation reported higher revenue but a mixed bottom line for the quarter ended March 31, 2026. Total revenue rose to $36.4 million from $30.3 million, driven by the 2025 acquisition of Akoya Biosciences, which contributed $8.7 million of product revenue and $3.7 million of service revenue. Legacy Quanterix product revenue fell as U.S. federal research funding cuts and macro-economic pressures reduced consumables demand and Accelerator Laboratory volumes.
Gross profit increased slightly to $15.6 million, but the gross margin declined to 43%, and the operating loss widened to $41.4 million due to a $19.3 million impairment of in‑process R&D tied to a terminated Akoya diagnostic development agreement. That termination also generated $21.6 million of one-time other income. Net loss improved to $17.5 million, or $0.37 per share. Quanterix ended the quarter with $36.2 million in cash and cash equivalents and $63.1 million in marketable securities and continues to target cash flow breakeven in the second half of 2026 while advancing its Alzheimer’s diagnostics strategy, including a 510(k) submission for a multi‑analyte blood test and Medicare pricing of $897 for its LucentAD Complete test.
Quanterix Corporation reported first-quarter 2026 revenue of $36.4 million, up 20% from $30.3 million a year earlier, driven by product and service growth across its Simoa and spatial biology platforms. GAAP gross margin was 42.7%, while adjusted gross margin improved to 50.9% from 49.7%.
The company posted a GAAP net loss of $17.5 million (or $0.37 per share), modestly better than the $20.5 million loss in 2025, and an adjusted EBITDA loss of $9.8 million versus $11.3 million. Quanterix ended the quarter with $102.6 million in cash, cash equivalents, marketable securities and restricted cash.
Management highlighted progress on integrating Akoya Biosciences, citing $85 million of cost synergies realized and a terminated off-market diagnostics contract that drove significant one-time charges and income. The Alzheimer’s diagnostics franchise continues to expand, with several clinical utility studies expected to complete and an FDA decision on a 510(k) application anticipated in the second half of 2026.
For full-year 2026, Quanterix reaffirmed revenue guidance of $169–$174 million, GAAP gross margin of 41–45% and adjusted gross margin of 49–53%. The company continues to expect cash flow breakeven in the second half of 2026 and to finish the year with roughly $100 million in cash and no debt.
Quanterix Corp Chief Operating Officer Michael Francis Miller reported routine equity compensation activity. He exercised 130 restricted stock units that converted into 130 shares of common stock on a one-for-one basis. To cover tax obligations, 39 common shares were disposed of through a tax-withholding transaction, not an open-market sale.
Following these transactions, Miller directly holds 32,613 shares of common stock and 549 restricted stock units that remain outstanding from a prior grant of 6,278 RSUs made on September 23, 2022.